Adding pan-AKT inhibitor capivasertib to docetaxel and prednisolone did not improve a composite progression-free survival in metastatic castration-resistant prostate cancer regardless of whether the PI3K/AKT/PTEN pathway was activated or not in the ProCAID trial (101). The gene discussed is AKT1; the disease is prostate carcinoma.